全文获取类型
收费全文 | 111003篇 |
免费 | 43385篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 1790篇 |
儿科学 | 5122篇 |
妇产科学 | 462篇 |
基础医学 | 24200篇 |
口腔科学 | 6643篇 |
临床医学 | 13888篇 |
内科学 | 26244篇 |
皮肤病学 | 4348篇 |
神经病学 | 18171篇 |
特种医学 | 5849篇 |
外科学 | 14978篇 |
综合类 | 27篇 |
一般理论 | 8篇 |
预防医学 | 7824篇 |
眼科学 | 1337篇 |
药学 | 9448篇 |
中国医学 | 1692篇 |
肿瘤学 | 12362篇 |
出版年
2024年 | 1篇 |
2023年 | 28篇 |
2022年 | 63篇 |
2021年 | 1538篇 |
2020年 | 5986篇 |
2019年 | 11344篇 |
2018年 | 10914篇 |
2017年 | 12147篇 |
2016年 | 11262篇 |
2015年 | 11159篇 |
2014年 | 10873篇 |
2013年 | 11100篇 |
2012年 | 10262篇 |
2011年 | 10156篇 |
2010年 | 8895篇 |
2009年 | 5368篇 |
2008年 | 5961篇 |
2007年 | 4331篇 |
2006年 | 4156篇 |
2005年 | 3950篇 |
2004年 | 3834篇 |
2003年 | 3496篇 |
2002年 | 3315篇 |
2001年 | 2514篇 |
2000年 | 1356篇 |
1999年 | 233篇 |
1998年 | 19篇 |
1997年 | 19篇 |
1996年 | 20篇 |
1995年 | 14篇 |
1994年 | 14篇 |
1993年 | 13篇 |
1992年 | 11篇 |
1991年 | 15篇 |
1990年 | 5篇 |
1989年 | 1篇 |
1988年 | 7篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 3篇 |
1979年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
161.
162.
163.
164.
165.
166.
Oral Everolimus for Treatment of a Giant Left Ventricular Rhabdomyoma in a Neonate—Rapid Tumor Regression Documented by Real Time 3D Echocardiography
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Robert Wagner M.D. Ph.D. Frank Thomas Riede M.D. Hiroshi Seki M.D. Frauke Hornemann M.D. Steffen Syrbe M.D. Ingo Daehnert M.D. Ph.D. Michael Weidenbach M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(12):1876-1879
The presented case reports on successful treatment with everolimus in a neonate with left ventricular giant rhabdomyoma. The authors used a different dosage regime compared to literature and documented rapid tumor regression by 3D echocardiography. 相似文献
167.
Three‐Dimensional Echocardiographic Evaluation of Mitral Apparatus during Preload Manipulation in Patients with Hypertrophic Cardiomyopathy
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Hyemoon Chung M.D. Ji Hyun Yoon M.D. Young Won Yoon M.D. Ph.D. Ji Young Chung B.N. Jung‐Joon Cha M.D. Jong‐Youn Kim M.D. Ph.D. Pil‐Ki Min M.D. Ph.D. Byoung‐Kwon Lee M.D. Ph.D. Bum‐Kee Hong M.D. Ph.D. Se‐Joong Rim M.D. Ph.D. Hyuck Moon Kwon M.D. Eui‐Young Choi M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(8):1261-1269
168.
Zhengxian Huang Nan Xie Haichao Liu Yuehan Wan Yue Zhu Ming Zhang Yifan Tao Han Zhou Xiqiang Liu Jinsong Hou Cheng Wang 《Journal of oral pathology & medicine》2019,48(9):788-798
It has been suggested that tumour‐infiltrating lymphocytes (TILs) are associated with the progression of oral squamous cell carcinoma (OSCC). However, the prognostic value of TILs is inconclusive due to the heterogeneity of immune cells within the tumour microenvironment. In this meta‐analysis, we aimed to assess the prognostic value of TILs in OSCC. The PubMed, Cochrane, Embase, Scopus and Web of Science databases were searched up to April 20, 2019, and 33 studies were ultimately included in this meta‐analysis. Our pooled meta‐analysis showed that high infiltration of CD8+ TILs, CD45RO+ TILs and CD57+ TILs favoured better overall survival (OS). However, high infiltration of CD68+ macrophages and CD163+ macrophages was associated with poor prognosis in OSCC. These findings suggest that CD8+ TILs, CD45RO+ TILs, CD57+ TILs, CD68+ macrophages and CD163+ macrophages might serve as novel prognostic factors and therapeutic targets in OSCC. 相似文献
169.
Stanislas Grassin‐Delyle Michaela Semeraro Frantz Foissac Naim Bouazza Haleema Shakur‐Still Ian Roberts Jean‐Marc Treluyer Saïk Urien 《Fundamental & clinical pharmacology》2019,33(6):670-678
Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss and death due to bleeding after trauma and post‐partum haemorrhage. One key issue for treatment success is early administration. While usually given intravenously, oral and intramuscular use would be useful in specific circumstances. Therefore, an understanding of TXA pharmacokinetics when given via different routes is valuable. The aim of this study was to perform an individual participant data meta‐analysis of pharmacokinetic studies with TXA given to healthy volunteers via different routes. We searched the following databases: PubMed, Web of Science, Wiley Online Library, Elsevier Science Direct and J‐STAGE. Individual subject data were extracted when available, otherwise arithmetic means were used. A population pharmacokinetic model was developed using nonlinear mixed effect modelling. Seven studies were included in the analysis with data from 10 patients for the IV route, six patients for the IM route and 114 patients for the oral route. The pharmacokinetics was ascribed to a two‐compartment model, and the main covariate was allometrically scaled bodyweight. Oral and IM bioavailabilities were 46 and 105%, respectively. For a 70 kg bodyweight, the population estimates were 7.6 L/h for clearance, 17.9 L for the volume of the central compartment, 2.5 L/h for the diffusional clearance and 16.6 L for the peripheral volume of distribution. Larger well‐designed studies are needed to describe the pharmacokinetics of TXA when given IM or as an oral solution before these can be recommended as alternatives to IV. 相似文献
170.
S. Natoli V. Oliveira P. Calabresi L. F. Maia A. Pisani 《European journal of neurology》2020,27(9):1764-1773
The current coronavirus disease (COVID‐19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has raised the possibility of potential neurotropic properties of this virus. Indeed, neurological sequelae of SARS‐CoV‐2 infection have already been reported and highlight the relevance of considering the neurological impact of coronavirus (CoV) from a translational perspective. Animal models of SARS and Middle East respiratory syndrome, caused by structurally similar CoVs during the 2002 and 2012 epidemics, have provided valuable data on nervous system involvement by CoVs and the potential for central nervous system spread of SARS‐CoV‐2. One key finding that may unify these pathogens is that all require angiotensin‐converting enzyme 2 as a cell entry receptor. The CoV spike glycoprotein, by which SARS‐CoV‐2 binds to cell membranes, binds angiotensin‐converting enzyme 2 with a higher affinity compared with SARS‐CoV. The expression of this receptor in neurons and endothelial cells hints that SARS‐CoV‐2 may have higher neuroinvasive potential compared with previous CoVs. However, it remains to be determined how such invasiveness might contribute to respiratory failure or cause direct neurological damage. Both direct and indirect mechanisms may be of relevance. Clinical heterogeneity potentially driven by differential host immune‐mediated responses will require extensive investigation. Development of disease models to anticipate emerging neurological complications and to explore mechanisms of direct or immune‐mediated pathogenicity in the short and medium term is therefore of great importance. In this brief review, we describe the current knowledge from models of previous CoV infections and discuss their potential relevance to COVID‐19. 相似文献